TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02870465

Intervention type: PROCEDURE
Intervention: Closed Reduction Internal Fixation
Description: K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.

Intervention type: PROCEDURE
Intervention: Closed Reduction Internal Fixation
Description: K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
Study: NCT01444911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Renewal Program
Description: The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Dilator
Description: Still vaginal dilator with lubricant.
Study: NCT04450030

Intervention type: DRUG
Intervention: Methyl Prednisolonate
Description: 2000mg intravenous methyl prednisolone per day for five consecutive days

Intervention type: PROCEDURE
Intervention: Immunoadsorption
Description: 6 courses of tryptophane-based immunoadsorption within up to 12 days
Study: NCT02538458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 % hypertonic saline up to 72H
Description: Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3 % hypertonic saline up to 24H
Description: * Treatment by inhalation of 3 % hypertonic saline, up to 24H.~* followed by 48h of placebo : isotonic saline inhalation. Placebo control group.
Study: NCT00077675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin or antistaphylococcal penicillin
Description: Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
Study: NCT02520752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT03048435

Intervention type: OTHER
Intervention: EORTC QLQ CX-24
Description: Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.

Intervention type: OTHER
Intervention: Physician Feedback Form
Description: This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
Study: NCT03243565

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OM-85
Description: OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
Study: NCT00484796

Intervention type: PROCEDURE
Intervention: MED-SEP
Description: intraoperative neurophysiological monitoring

Intervention type: PROCEDURE
Intervention: TRI-SEP
Description: intraoperative neurophysiologic monitoring

Intervention type: PROCEDURE
Intervention: neuropsychological tests
Description: neurological short- and longterm outcome
Study: NCT01041950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar drainage
Description: Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
Study: NCT03317743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV140101 (IDX-1197)
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Study: NCT04188132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG -BCI based Feedback for rehabilitation
Description: Subjects will undergo EEG based BCI as feedback for rehabilitation
Study: NCT03672149

Intervention type: DRUG
Group type: OTHER
Intervention: Cefazolin
Description: Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Cefazolin
Description: Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Cefazolin
Description: Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
Study: NCT02527473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dispatcher-Assisted Basic Life Support CPR Education
Description: The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.~The one hour training session is split into four parts:~1. Video self-instruction manikin practice (30 min), including a brief introduction to AED.~2. Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer~3. Debriefing (15 min): Questions, answers and reflection~4. Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone
Study: NCT05141838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Description: Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Description: Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
Study: NCT02306811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study: NCT01924299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Administered orally
Study: NCT05797688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Celution System
Description: The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.
Study: NCT00944788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: qi-gong
Description: Physical activity similar to tai-chi
Study: NCT01234896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Medicated Gum
Description: Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg Nicotine Gum
Description: Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg Nicotine Gum
Description: Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg Nicotine Lozenge
Description: Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
Study: NCT00830115

Intervention type: DRUG
Intervention: Pantoprazole
Description: Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
Study: NCT02685657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Selumetinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT03615118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR/SMS
Description: Daily SMS messages asking participants to report their mood on a 1 to 9 scale; An automated phone system for monitoring and improving self-care and health outcomes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Daily SMS messages asking participants to report their mood on a 1 to 9 scale
Study: NCT02349737

Intervention type: OTHER
Intervention: Exposure to BIA interference with the ICD
Description: Exposure to BIA interference with the ICD
Study: NCT03946293

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White Bread
Description: White bread made with commercial white flour with bran/fibre removed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain bread
Description: Wholegrain bread made with commercial wholegrain flour.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wholegrain Enzyme
Description: Wholegrain bread made with enzyme-treated commercial wholegrain flour.
Study: NCT02895412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived WT1-CTL and P-CTL
Description: Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses.
Study: NCT00815204

Intervention type: PROCEDURE
Intervention: MRI of the pituitary
Description: Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume

Intervention type: PROCEDURE
Intervention: MRI of the pituitary
Description: Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume

Intervention type: PROCEDURE
Intervention: MRI of the pituitary
Description: Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume

Intervention type: PROCEDURE
Intervention: DEX/CRH test
Description: Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.

Intervention type: PROCEDURE
Intervention: DEX/CRH test
Description: Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.

Intervention type: PROCEDURE
Intervention: DEX/CRH test
Description: Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
Study: NCT02255643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Change of PMT setting
Description: The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Change of PMT setting
Description: The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Change of PMT setting
Description: The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
Study: NCT02520752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study: NCT03335293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mcg Epinephrine
Description: This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mcg Epinephrine
Description: This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
Study: NCT03457480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Read computer messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Attend focus group
Study: NCT04588311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa 40000 UNT/ML
Description: Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
Study: NCT00971958

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision
Description: Neonatal circumcision using one of three non-experimental, widely available devices.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision
Description: Neonatal circumcision using one of three non-experimental, widely available devices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mogen Clamp
Description: Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastibell
Description: The plastibell is a one-time use device for the circumcision of male neonates, infants and children.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastibell
Description: The plastibell is a one-time use device for the circumcision of male neonates, infants and children.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastibell
Description: The plastibell is a one-time use device for the circumcision of male neonates, infants and children.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuCirc
Description: AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuCirc
Description: AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuCirc
Description: AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
Study: NCT04335318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-assisted colonoscopy
Description: Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
Study: NCT03457480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive text messages
Study: NCT00228423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg daily
Description: Daily dose of 75 mg Clopidogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water pill daily
Description: Daily dose of water pill (placebo)
Study: NCT03535779

Intervention type: BIOLOGICAL
Intervention: Hepatitis B
Description: The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population

Intervention type: BIOLOGICAL
Intervention: Tetanus Toxoid
Description: The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
Study: NCT03911518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop drainage
Description: Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and drainage
Description: The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
Study: NCT02537366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02077439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Robotic Training
Description: Training for 20 sessions for one hour, 3-5 times per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand and Arm Robotic Training
Description: Training for 20 sessions for one hour, 3-5 times per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Training for 20 sessions for one hour, 3-5 times per week.
Study: NCT03487783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Oral Solution
Description: Aripiprazole 2-20 mg/day (2-20 mL/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Placebo 2-20 mg/day (2-20 mL/day)
Study: NCT01939496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
Study: NCT03035721

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low protein formula
Description: Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard protein formula
Description: Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
Study: NCT01632761

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 .

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Study: NCT00673387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day
Study: NCT01014806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine
Description: Single dose; 0.5mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza VLP Vaccine
Description: Single dose; 0.5mL
Study: NCT00673387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day
Study: NCT02798874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
Study: NCT00673387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-P
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo-P
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo-M
Description: subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-M
Description: subcutaneous injection, twice a day
Study: NCT04421586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VISTA
Description: VISTA will be an educational intervention.
Study: NCT05301530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faceptor
Description: NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.